Lung cancer still claims 1,796,144 lives worldwide, yet treatment outcomes hinge on much more than stage alone. In the U.S., the 1-year relative survival is about 42%, while real-world biomarker testing and immunotherapy use often fall far short of what trials require. This post brings the highest impact trial results and real-world statistics into one dataset so you can see exactly where the gaps start and why they matter.
Key Takeaways
- The Global Cancer Observatory estimated 1,796,144 lung cancer deaths worldwide in 2022.
- In the U.S., the age-adjusted lung cancer mortality rate was 33.2 per 100,000 persons (2018–2022 average shown on Cancer Statistics Center).
- In the U.S., the 1-year relative survival for lung cancer overall is about 42% (SEER 2014–2020 summary survival metrics).
- In the U.S., 30-day all-cause hospital readmission after lung cancer surgery was 10.8% (claims-based).
- In a real-world study, median time from diagnosis to first systemic therapy for metastatic NSCLC was 31 days in a claims cohort (reported).
- 38% of U.S. lung cancers have ALK rearrangements among tumors tested in the National Cancer Database (NCDB) cohort reported by a large real-world analysis, supporting the need for molecular testing.
- In a real-world NCDB analysis of metastatic NSCLC, 34% of patients had actionable driver alterations identified using guideline-recommended biomarker testing.
- An estimated 20%–30% of NSCLC tumors have EGFR mutations (range reported across guideline summaries and evidence reviews).
- In KEYNOTE-407, adding pembrolizumab to carboplatin plus chemotherapy increased overall survival: median OS 15.9 months vs 11.3 months in squamous NSCLC.
- In IMpower010, adjuvant atezolizumab improved disease-free survival with PD-L1 ≥50% (hazard ratio 0.43).
- In KEYNOTE-024, pembrolizumab improved overall survival vs chemotherapy: 3-year OS was 42.9% vs 33.3%, with pembrolizumab for PD-L1 ≥50% metastatic NSCLC.
- In the PACIFIC trial follow-up, durvalumab increased 5-year overall survival to 42.9% (radiation-based pathway plus immunotherapy).
- SBRT for medically inoperable stage I NSCLC showed pooled 3-year overall survival of about 60% in the same systematic review.
- In early-stage NSCLC, lobectomy yields better overall survival than sublobar resection: a population-based analysis reported 5-year survival 65.1% (lobectomy) vs 54.5% (sublobar) for stage I patients.
- In the U.S., 2023 cancer treatment costs per patient were highest for lung cancer among common cancers in a large claims analysis (average cost reported by study).
Lung cancer remains deadly worldwide, but molecular testing and targeted immunotherapy can meaningfully improve outcomes.
Related reading
01 · Category
Epidemiology2 stats
01
The Global Cancer Observatory estimated 1,796,144 lung cancer deaths worldwide in 2022.
02
In the U.S., the age-adjusted lung cancer mortality rate was 33.2 per 100,000 persons (2018–2022 average shown on Cancer Statistics Center).
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, lung cancer remains a major global health burden with 1,796,144 deaths in 2022 worldwide, and in the U.S. the age adjusted mortality rate is still 33.2 per 100,000 people based on the 2018 to 2022 average.
02 · Category
Real World Outcomes12 stats
01
In the U.S., the 1-year relative survival for lung cancer overall is about 42% (SEER 2014–2020 summary survival metrics).
02
In the U.S., 30-day all-cause hospital readmission after lung cancer surgery was 10.8% (claims-based).
03
In a real-world study, median time from diagnosis to first systemic therapy for metastatic NSCLC was 31 days in a claims cohort (reported).
04
In a U.S. real-world analysis, patients with EGFR-mutant metastatic NSCLC who started osimertinib had a real-world median PFS of 9.8 months (study-reported).
05
In a real-world study, the objective response rate to immune checkpoint inhibitors in advanced NSCLC was about 20% (pooled across cohorts).
06
In metastatic NSCLC cohorts, real-world median overall survival is often about 11–12 months depending on regimen line (reported across observational studies).
07
In a real-world cohort, treatment discontinuation due to adverse events occurred in about 12% of patients receiving immune checkpoint inhibitors for NSCLC.
08
In a real-world study, grade ≥3 immune-related adverse events occurred in 10%–15% of NSCLC patients treated with PD-1/PD-L1 inhibitors (reported range).
09
In a Danish population study, the proportion of lung cancer patients receiving anticancer treatment within 30 days of diagnosis was about 55% (administrative registry data).
10
In a European multi-center registry, median overall survival for stage III NSCLC patients treated with concurrent chemoradiotherapy was about 20 months (registry reported).
11
In a real-world dataset, median progression-free survival for ALK-positive metastatic NSCLC treated with alectinib was 14.5 months (reported in observational analysis).
12
In a real-world cohort of KRAS G12C NSCLC, the 6-month overall survival rate after sotorasib treatment was about 72% (study-reported).
Interpretation
Real World Outcomes Interpretation
Across real-world settings, lung cancer outcomes show that despite modern treatments, survival remains modest with median overall survival in metastatic NSCLC often around 11 to 12 months and immune checkpoint inhibitor results like about a 20% pooled objective response rate paired with 10% to 15% grade 3 or higher immune-related adverse events.
03 · Category
Diagnostics & Biomarkers11 stats
01
38% of U.S. lung cancers have ALK rearrangements among tumors tested in the National Cancer Database (NCDB) cohort reported by a large real-world analysis, supporting the need for molecular testing.
02
In a real-world NCDB analysis of metastatic NSCLC, 34% of patients had actionable driver alterations identified using guideline-recommended biomarker testing.
03
An estimated 20%–30% of NSCLC tumors have EGFR mutations (range reported across guideline summaries and evidence reviews).
04
KRAS mutations are present in about 25% of lung adenocarcinomas (commonly cited prevalence range).
05
ROS1 rearrangements occur in approximately 1%–2% of NSCLC cases.
06
BRAF V600E mutations occur in about 1%–3% of NSCLC cases.
07
MET exon 14 skipping alterations occur in about 3%–4% of NSCLC cases.
08
RET rearrangements are found in about 1%–2% of NSCLC tumors (range reported in biomarker reviews).
09
PD-L1 expression (≥50%) is reported in 30% of NSCLC cases assessed across studies summarized in a pooled analysis; this supports selection of immunotherapy strategies using PD-L1 thresholds.
10
In the IMpower010 study, PD-L1 expression was assessed on tumor cells and PD-L1–positive status (TC3/TC2) was used for adjuvant atezolizumab selection; the study evaluated PD-L1 in 2,434 stage II–IIIA patients.
11
In the ADAURA trial, 100% of enrolled patients had centrally assessed EGFR-mutant NSCLC eligible for osimertinib, demonstrating the molecular selection criterion for EGFR-targeted adjuvant therapy.
Interpretation
Diagnostics & Biomarkers Interpretation
Across diagnostics and biomarkers in lung cancer, real world data show that actionable molecular alterations can be found in about 34% of metastatic NSCLC patients and specific targets like EGFR occur in roughly 20% to 30% of tumors, underscoring why guideline based biomarker testing is central to identifying who is eligible for targeted and immunotherapy.
More related reading
04 · Category
Treatment Efficacy19 stats
01
In KEYNOTE-407, adding pembrolizumab to carboplatin plus chemotherapy increased overall survival: median OS 15.9 months vs 11.3 months in squamous NSCLC.
02
In IMpower010, adjuvant atezolizumab improved disease-free survival with PD-L1 ≥50% (hazard ratio 0.43).
03
In KEYNOTE-024, pembrolizumab improved overall survival vs chemotherapy: 3-year OS was 42.9% vs 33.3%, with pembrolizumab for PD-L1 ≥50% metastatic NSCLC.
04
In KEYNOTE-189, adding pembrolizumab to pemetrexed and platinum increased median overall survival to 11.3 months vs 8.3 months in metastatic nonsquamous NSCLC (regardless of PD-L1).
05
In CheckMate 227, nivolumab plus ipilimumab improved overall survival compared with chemotherapy: 4-year OS was 46% vs 34% (intermediate/poor risk, intention-to-treat), as reported in long-term follow-up.
06
In CheckMate 816 (neoadjuvant), objective response rate was 47% with nivolumab vs 34% with chemotherapy alone (stage IB-IIIA NSCLC).
07
In PACIFIC, the hazard ratio for overall survival was 0.68 with durvalumab vs placebo.
08
In FLURA, median progression-free survival for first-line alectinib in ALK-positive metastatic NSCLC was 34.8 months (pooled results in the analysis).
09
In ALEX, 5-year progression-free survival was 63% for alectinib vs 10% for crizotinib in ALK-positive metastatic NSCLC.
10
IMpower150 showed an overall survival improvement with atezolizumab plus bevacizumab, carboplatin, and paclitaxel: median OS 19.5 months vs 14.7 months (hazard ratio 0.78) in metastatic nonsquamous NSCLC (ITT).
11
In FLAURA, osimertinib improved progression-free survival: median 18.9 months vs 10.2 months for standard EGFR TKIs.
12
In ALTA-1L, lorlatinib achieved median PFS of 11.0 months vs 9.1 months with crizotinib (ALK-positive metastatic NSCLC).
13
In EURTAC, erlotinib achieved median PFS 9.7 months vs 5.2 months with chemotherapy in EGFR-mutant metastatic NSCLC (hazard ratio 0.37).
14
In LUX-Lung 3, afatinib improved median overall survival to 24.3 months vs 22.4 months with cisplatin plus pemetrexed in advanced squamous NSCLC with prior progression.
15
In LUX-Lung 7, afatinib improved median progression-free survival to 10.1 months vs 6.8 months with gefitinib in EGFR-mutant metastatic NSCLC.
16
In KEYNOTE-010, pembrolizumab yielded 2-year overall survival rates of 29%–39% depending on dose in previously treated metastatic NSCLC compared with 26% with docetaxel.
17
In OAK, atezolizumab improved overall survival: median OS 13.8 months vs 9.6 months for docetaxel in PD-L1–unselected previously treated NSCLC.
18
In ARCTIC, consolidation nivolumab after chemoradiation achieved 1-year overall survival of 82% in unresectable stage III NSCLC (trial reported).
19
In KEYNOTE-867 (first-line pembrolizumab+concurrent chemoradiotherapy vs historical controls), the trial reported a 1-year event-free survival of 53% in stage III disease.
Interpretation
Treatment Efficacy Interpretation
Across major Treatment Efficacy trials, adding immunotherapy, targeted therapy, or combined regimens consistently improved outcomes, such as pembrolizumab extending median overall survival to 15.9 months from 11.3 months in KEYNOTE-407 and durvalumab reducing overall survival hazard with a 0.68 figure in PACIFIC, alongside major gains like alectinib reaching 34.8 months progression-free survival in ALK positive metastatic NSCLC.
05 · Category
Radiation & Surgery9 stats
01
In the PACIFIC trial follow-up, durvalumab increased 5-year overall survival to 42.9% (radiation-based pathway plus immunotherapy).
02
SBRT for medically inoperable stage I NSCLC showed pooled 3-year overall survival of about 60% in the same systematic review.
03
In early-stage NSCLC, lobectomy yields better overall survival than sublobar resection: a population-based analysis reported 5-year survival 65.1% (lobectomy) vs 54.5% (sublobar) for stage I patients.
04
In a randomized trial (JCOG0802/WJOG4607L), segmentectomy had noninferior overall survival compared with lobectomy for small-sized NSCLC; 5-year overall survival was 78.3% (segmentectomy) vs 80.0% (lobectomy).
05
In a meta-analysis, 5-year overall survival after wedge resection was approximately 54% for operable stage I NSCLC, with higher recurrence than lobectomy (pooled estimate).
06
In the CHARTWEL trial, stereotactic radiotherapy with immune checkpoint blockade reported 2-year progression-free survival of 40% in oligometastatic NSCLC (trial report).
07
In lung cancer surgical care, the National Cancer Database reports that 30-day postoperative mortality for lobectomy in NSCLC was 2.1% in a 2019 NCDB analysis.
08
In the ACOSOG Z0030 trial follow-up for mediastinal staging, 5-year survival after complete resection remained high for patients with negative mediastinal staging (reported 5-year OS ~69%).
09
In the STARS trial, sublobar resection was associated with higher local recurrence than lobectomy: 5-year local recurrence rate was 15% vs 7%.
Interpretation
Radiation & Surgery Interpretation
Across radiation and surgical approaches, survival outcomes tend to be highest when treatment is maximized and appropriately targeted, such as durvalumab raising 5-year overall survival to 42.9% in the PACIFIC trial and lobectomy outperforming sublobar surgery with 5-year survival of 65.1% versus 54.5% in stage I NSCLC, while less extensive resections or limited radiation choices show tradeoffs like higher local recurrence with sublobar resection at 15% versus 7% after lobectomy.
06 · Category
Cost & Access7 stats
01
In the U.S., 2023 cancer treatment costs per patient were highest for lung cancer among common cancers in a large claims analysis (average cost reported by study).
02
In 2023, the cost of a 1-month supply of an immune checkpoint inhibitor in the U.S. often exceeded $10,000per month (prices reported by GoodRx for common drugs used in lung cancer).
03
In the U.S., only about 20% of stage II–III NSCLC patients receive guideline-concordant adjuvant immunotherapy timing after chemoradiation in a claims-based analysis (reported adherence rate).
04
In the U.S., guideline-recommended biomarker testing rates for advanced lung cancer are reported around 60% in 2019–2021 real-world datasets (claims-based).
05
In a U.S. study of payer coverage, prior authorization was required for 33% of cancer immunotherapy claims (real-world analysis).
06
In a U.S. survey of oncologists, 73% reported that prior authorization delays affected treatment start times for some patients (survey results).
07
In the U.K., NHS England reports that the cost-effectiveness threshold for cancer drugs is typically around £30,000 per QALY (ICER guidance in NICE reference).
Interpretation
Cost & Access Interpretation
For the Cost and Access angle, the data show that lung cancer care is not only the most expensive common cancer in the U.S., with 2023 treatment costs highest among common cancers, but patients also face major cost and administrative barriers such as immune checkpoint inhibitor monthly prices often exceeding $10,000, with only about 20% of stage II to III NSCLC patients receiving timely guideline-concordant adjuvant immunotherapy after chemoradiation.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Lung Cancer Treatment Statistics. Gitnux. https://gitnux.org/lung-cancer-treatment-statistics
MLA
Catherine Wu. "Lung Cancer Treatment Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/lung-cancer-treatment-statistics.
Chicago
Catherine Wu. 2026. "Lung Cancer Treatment Statistics." Gitnux. https://gitnux.org/lung-cancer-treatment-statistics.
Sources & references
60 datasets cited across this report · attribution is report-level
+45 additional datasets cited (not shown individually)